Overview


A group of nanocarriers for drug administration is known as polymer-drug conjugates, it can delay drug deterioration, inhibit premature drug interaction with the biological environment, and accelerate medication absorption into tissues (by enhanced permeability and retention effect or active targeting). Since their pharmacokinetic profiles differ from those of their parent drugs, polymer-drug conjugates are frequently regarded as novel chemical entities (NCES). The term "polymeric prodrug" refers to a drug that has been conjugated with a polymer.

Nanosized drug compounds called polymer-drug conjugates are presently used to treat hepatitis and cancer. Polymers sensitive to particular enzymes are now being created in order to identify these enzymes in diseased tissue. The market for polymer-drug conjugates is anticipated to expand quickly as novel pipeline medicines are created through this process. The growth in the polymer-drug conjugates market is anticipated to be constrained by the small number of applications for these compounds. When the polymer and the medication make a covalent bond, a polymer-drug conjugate is created. However, not all molecular functional groups found in medicines are appropriate for covalent conjugation. The medicines only work to cure cancer because they are only released into cancerous tissues or cells. Intravenous ubenimex injections containing these polymers substantially reduce tumour growth in mice. Such outcomes are anticipated to spur market expansion.

FutureWise Market Research has published a report that provides an insightful analysis of Polymer Drug Conjugates Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

By the end of the forecast period FutureWise research analysts projects that Polymer Drug Conjugates Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  •  3S Bio
  • ABEONA THERAPEUTICS
  • Abramson Cancer Center
  •  ACCESS PHARMACEUTICALS
  • ADAMA  
  • EYETECH  
  • FERRING
  • FLAMEL TECHNOLOGIES
  • Genentech    
  • GlaxoSmithKline    
  • Gowan
  • Gynecologic Oncology Group Foundation    
  • JenKem Technology    
  • Landec    
  • Lipotek

(Note: The list of the major players will be updated with the latest market scenario and trends)

The polymer drug conjugates (PDC) market is a growing field within the pharmaceutical industry, which involves the development of new drug delivery systems using polymers. Polymer drug conjugates are essentially polymeric materials that have been chemically attached to a drug molecule, thereby enhancing the drug's stability, solubility, and pharmacokinetics. One of the key drivers of the PDC market is the growing incidence of chronic diseases, such as cancer and autoimmune disorders. PDCs have the potential to improve the efficacy and safety of these drugs by reducing toxicity to healthy tissues and increasing the concentration of the drug at the target site. Another driver of the PDC market is the increasing demand for biologics and biosimilars, which are large, complex molecules that are difficult to deliver through traditional drug delivery systems. PDCs can improve the stability and half-life of these molecules, making them more effective and easier to administer.

The PDC market is also driven by advances in polymer chemistry and drug conjugation technology. New polymers and conjugation techniques are being developed that can improve drug loading, release profiles, and targeting specificity. These advances are enabling the development of new PDCs that can target specific cell types, cross the blood-brain barrier, and deliver drugs to intracellular targets.

However, potential for immunogenicity and toxicity produced by PDCs can be a constraint to the target market growth. PDCs can trigger an immune response or cause toxicity if the polymer carrier or drug conjugation is not well-tolerated by the body. This can limit the effectiveness of the drug and lead to adverse side effects.

By Product Type

  • Polymer-Dox Conjugates
  • Polymer-Paclitaxel Conjugates
  • Polymer-Camptothecin Conjugates
  • Polymer-Platinate Conjugates

By Application

  • Cancer Treatment
  • Leukemia
  • Hepatitis
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. A growing number of clinical trials in the United States have led to projections that North America will retain the largest share of the worldwide market for polymer-drug conjugates. Furthermore, during the projection period, the market for polymer drug conjugates in North America is anticipated to expand significantly as a result of rising research on novel Drug Delivery Systems (DDS) in the region. Additionally, on a global scale, based on application; cancer holds highest market share of 48.7% in 2022.

  • Tier 1 players- established companies in the market with major market share
  • Tier 2 players
  • New Entrants
  • Emerging players which are growing rapidly

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data points affecting market growth

  • To provide with an exhaustive analysis on the of Polymer Drug Conjugates Market By Product type, By Application and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization services offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Polymer Drug Conjugates Market Variables, Trends and Scope
    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Polymer Drug Conjugates Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Polymer Drug Conjugates Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Polymer Drug Conjugates Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Polymer-Dox Conjugates
        2. Polymer-Paclitaxel Conjugates
        3. Polymer-Camptothecin Conjugates
        4. Polymer-Platinate Conjugates

  • 8.   Polymer Drug Conjugates Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cancer Treatment
        2. Leukemia
        3. Hepatitis
        4. Others

  • 9.   North America Polymer Drug Conjugates Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Polymer Drug Conjugates Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Polymer Drug Conjugates Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Polymer Drug Conjugates Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. 3S Bio
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. ABEONA THERAPEUTICS
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Abramson Cancer Center
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. ACCESS PHARMACEUTICALS
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. ADAMA
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. EYETECH
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. FERRING
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. FLAMEL TECHNOLOGIES
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Genentech
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GlaxoSmithKline
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Gowan
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Gynecologic Oncology Group Foundation
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. JenKem Technology
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Landec
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Lipotek
          15. 1. Company Overview
          15. 2. Product Portfolio
          15. 3. SWOT Analysis
          15. 4. Financial Overview
          15. 5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients